EYPT EyePoint, Inc.
Price Chart
Executive Summary
EyePoint reported a significant year-over-year decline in revenue and increased losses for Q4 and full-year 2025, driven by the completion of deferred revenue recognition from its YUTIQ license agreement. However, the company highlighted strong clinical progress with its lead candidate DURAVYU, including ongoing Phase 3 trials in wet AMD and DME, and secured a $306 million cash runway into Q4 2027. The appointment of a new Chief Commercial Officer signals preparation for a potential 2026-2027 product launch.
Key Financial Metrics
Actionable Insight
Traders should monitor upcoming Phase 3 data readouts for DURAVYU in mid-2026 as a key catalyst. While current financials are deteriorating due to R&D investment and lapping of prior revenue, the cash runway supports execution through 2027. A successful DURAVYU readout could validate the investment story despite near-term losses.
Key Facts
- Q4 2025 revenue dropped to $0.62 million from $11.59 million in Q4 2024 (-94.6% YoY)
- Full-year 2025 revenue declined to $31.37 million from $43.27 million in 2024 (-27.5% YoY)
- Net loss widened to $67.6 million in Q4 2025 vs $41.4 million in Q4 2024
- Full-year net loss increased to $232.0 million in 2025 vs $130.9 million in 2024
- Cash, cash equivalents, and investments totaled $306 million as of December 31, 2025
- DURAVYU Phase 3 topline data in wet AMD expected beginning mid-2026
- First patient dosed in Phase 3 COMO and CAPRI trials for DME with data expected in second half of 2027
- Michael Campbell appointed Chief Commercial Officer to lead DURAVYU launch
Financial Impact
Revenue down $11.9M YoY; operating expenses up $85.7M YoY; net loss increased by $101.1M; cash balance decreased by $65M year-over-year
Risk Factors
- Clinical trial failure or delay for DURAVYU could severely impact valuation
- Continuing high R&D spend may pressure cash runway if milestones are delayed
- FDA regulatory hurdles or warning letter issues at Watertown facility could delay approval
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3249208 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 14, 2026
6d ago
|
8-K
| $13.31 awaiting T+20 | awaiting T+20 | — | $12.50 (−6.09%) |
|
May 14, 2026
6d ago
|
Press Release
| — | awaiting T+20 | — | — |
|
Apr 17, 2026
4w ago
|
144
| $15.07 $11.70 | ▼ −22.36% | ▼ −26.56% | $12.50 (−17.05%) |
|
Apr 13, 2026
5w ago
|
8-K
| $14.34 $13.98 | ▼ −2.51% | ▼ −8.81% | $12.50 (−12.83%) |
|
Mar 4, 2026
11w ago
|
Press Release
| $18.00 $13.02 | ▼ −27.67% | ▼ −23.25% | $12.50 (−30.56%) |
|
Mar 2, 2026
11w ago
|
Press Release
| $18.34 $11.85 | ▼ −35.39% | ▼ −27.45% | $12.50 (−31.84%) |
|
Feb 28, 2026
11w ago
|
Institutional Cluster
| $18.34 $11.85 | ▼ −35.39% | ▼ −27.45% | $12.50 (−31.84%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access